The term "materials" covers every medium used to provide information to healthcare professionals — product information summaries, presentation slides, brochures, digital content, and more. Chapter 2, Section 3 of the Guidelines applies to all of them. The central requirement is pre-use review: a mandatory gate before any material reaches the clinical environment, rather than a recall process triggered by problems discovered in the field.

Three requirements define this section. First, materials must comply with applicable laws and the Guidelines, with reference to international standards as well. Second, materials must be updated when new evidence emerges. Third, every material must pass through the supervisory department's pre-use review and receive approval based on the advisory committee's input. Outsourcing the review work is permitted; outsourcing the approval responsibility is not.

01Compliance with Laws and Guidelines — The Baseline for Creation

Materials must be created in compliance with applicable laws and regulations, including the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, advertising standards, and the Guidelines themselves. Companies must also endeavor to comply with guidelines issued by international organizations such as WHO and ICH, and by relevant industry associations. The "endeavor" phrasing signals a best-efforts obligation for international standards, while compliance with domestic law is non-negotiable.

So what (what this means in practice): "We didn't violate any law" is not a complete defense if the material fails to meet the standards set by the Guidelines or recognized international frameworks. The compliance baseline is deliberately set higher than the legal minimum.

So why (the rationale): Domestic regulation cannot anticipate every nuance of data presentation and safety communication. International guidelines — developed through broader scientific and ethical consensus — often provide more granular standards for issues such as statistical presentation and benefit-risk balance. Incorporating these reduces the risk of technically lawful but misleading materials.

02Updating Materials as Knowledge Evolves — No Static Approvals

Materials that were compliant and accurate at the time of initial approval do not automatically remain so. When new scientific evidence is published, or when the package insert is revised, companies must update and correct materials accordingly. "It was accurate when we made it" does not justify continuing to use a material that no longer reflects current knowledge.

So what (what this means in practice): Material lifecycle management is a compliance requirement. Continuing to distribute materials after a new safety signal emerges or after the package insert is updated is a violation, even if the material was properly approved at the time of creation.

So why (the rationale): Medical science does not stand still. Safety information in particular is often supplemented or revised post-approval as real-world evidence accumulates. Outdated materials in active circulation create the risk that prescribers make clinical decisions based on a scientific picture that has since changed.

03Pre-Use Review by the Supervisory Department — The Gate Before Distribution

Every material must undergo review by the Sales Information Activities Supervisory Department before it is used. This is a mandatory pre-use gate, not a post-use audit. The framework explicitly rejects "use it and correct problems when they arise" as an acceptable approach.

So what (what this means in practice): A field representative cannot exercise independent judgment to use a material on the grounds that "it looks fine." Supervisory department clearance is a prerequisite for use, not a recommendation to seek when in doubt.

So why (the rationale): Once a material has been handed to a healthcare professional, its influence on clinical thinking has begun. Recalling it does not undo what was communicated. Front-loading quality assurance — catching problems before distribution — is the only mechanism that reliably prevents problematic content from reaching clinical decision-making.

04Advisory Committee Input and Approval — A Two-Stage Decision

The approval process does not end with the supervisory department's review. Materials must be approved taking into account the advice of the Review and Supervisory Committee. Final approval authority and responsibility rests with the supervisory department (and ultimately with management), but the committee's advisory input is formally built into the process, enabling multi-perspective evaluation before approval is granted.

So what (what this means in practice): Approval is not a unilateral decision by the supervisory department. The committee's advisory role must be meaningfully incorporated — not treated as a formality to be bypassed under time pressure.

So why (the rationale): Any single review layer can develop consistent blind spots over time, particularly when the same reviewers assess similar materials repeatedly. The committee, which includes members external to the company, disrupts the normalization of borderline practices that internal reviewers may stop noticing.

05Outsourcing the Review — Work Can Be Delegated, Responsibility Cannot

The actual review work — checking materials for compliance — may be delegated to external specialists. However, the responsibility for the approval decision does not transfer to the external party. The supervisory department retains the obligation to make the approval judgment, and that responsibility flows up to management. Outsourcing is a delegation of tasks, not a delegation of accountability.

So what (what this means in practice): If an external reviewer says "this material is compliant," that assessment does not constitute the required approval. The supervisory department must make the final approval decision — it cannot simply ratify a contractor's output.

So why (the rationale): Without this provision, companies could insulate themselves from accountability by routing all approvals through contractors. The requirement that approval responsibility remain inside the company ensures that the organization that benefits commercially from the material also bears the full risk of its content.

Summary

Section 3 of Chapter 2 creates a full lifecycle quality framework for promotional materials. It begins at creation (compliance with laws and guidelines), extends through the material's active life (updating when knowledge evolves), and structures the approval process as a two-stage gate (supervisory department review plus advisory committee input). Outsourcing review work does not move the approval responsibility outside the company.

The provision's defining logic is temporal: problems must be caught before distribution, not discovered in the field. Placing the quality gate at the entry point — before materials reach healthcare professionals — is the structural commitment that makes pre-use review more than a procedural formality.